 |
 Video: What is a Stock Split?
|
|
|
| Acasti Pharma is a biopharmaceutical company that is focused on developing and commercializing products for rare and orphan diseases by using its drug delivery technologies. Co.'s primary drug candidate, GTX-104, is an IV formulation of nimodipine designed to treat subarachnoid hemorrhage, a rare brain disorder. Co.'s other drug candidates are: GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia, an orphan pediatric genetic neurodegenerative disorder in young children; and GTX-101, which is a topical bioadhesive film-forming bupivacaine spray for Postherpetic Neuralgia, which causes debilitating pain following infection by the shingles virus. According to our ACST split history records, Acasti Pharma has had 4 splits. | |
|
Acasti Pharma (ACST) has 4 splits in our ACST split history database. The first split for ACST took place on December 12, 2003. This was a 1 for 89 reverse split, meaning for each 89 shares of ACST owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 11.2359550561798 share position following the split. ACST's second split took place on October 15, 2015. This was a 1 for 10 reverse split, meaning for each 10 shares of ACST owned pre-split, the shareholder now owned 1 share. For example, a 11.2359550561798 share position pre-split, became a 1.12359550561798 share position following the split. ACST's third split took place on August 31, 2021. This was a 1 for 8 reverse split, meaning for each 8 shares of ACST owned pre-split, the shareholder now owned 1 share. For example, a 1.12359550561798 share position pre-split, became a 0.140449438202247 share position following the split. ACST's 4th split took place on July 10, 2023. This was a 1 for 6 reverse split, meaning for each 6 shares of ACST owned pre-split, the shareholder now owned 1 share. For example, a 0.140449438202247 share position pre-split, became a 0.0234082397003745 share position following the split.
When a company such as Acasti Pharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ACST split history from start to finish, an original position size of 1000 shares would have turned into 0.0234082397003745 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acasti Pharma shares, starting with a $10,000 purchase of ACST, presented on a split-history-adjusted basis factoring in the complete ACST split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/10/2013 |
|
| End date: |
12/06/2023 |
|
| Start price/share: |
$561.60 |
|
| End price/share: |
$2.23 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.60% |
|
| Average Annual Total Return: |
-42.49% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$39.70 |
|
| Years: |
9.99 |
|
|
|
| Date |
Ratio |
| 12/12/2003 | 1 for 89 | | 10/15/2015 | 1 for 10 | | 08/31/2021 | 1 for 8 | | 07/10/2023 | 1 for 6 |
|
|
Free ACST Email Alerts:
